Annual Securities Report — FY2025
What Delta-Fly Pharma,Inc. reported for the period from 2025-04-01 to 2026-03-31. Filed by ＤｅｌｔａーＦｌｙ Ｐｈａｒｍａ株式会社
Filed 2026-06-24View the original on EDINET
How much it says
33Thin
What moved here
8named for the first time
Its own wording
14terms
Which filing this is
26/ 26newest
No officer data yetThis company's filings have not been read for officers yet. Nothing is missing from the filings — the roster simply has not been extracted.
The gist
During the fiscal year, the company advanced clinical work and preparations for each of the development products DFP-10917, DFP-14323, DFP-17729, DFP-11207, DFP-14927 and DFP-10825. However, it received no milestone or other revenue and generated no business revenue. Operating loss was ¥1,605 million, and cash and cash equivalents were ¥145 million. The company secured financing cash through such means as the exercise of share acquisition rights.
Komori's summary of this document, not the document's own words.33Thin
How much this filing saysA weighted roll-up of 11 rubric dimensions, each scored from a fixed set of questions asked against this filing — built only from the 36 this document could answer. It measures how specific the disclosure is, not whether the company is doing well. Derived from the data, not editorial.
73
Detailed
31
Thin
8
Almost nothing
50
Typical
0
Almost nothing
0
Almost nothing
27
Almost nothing
62
Detailed
7
Almost nothing
55
Typical
50
Typical
R&D spend13億円Money spent making new things.
Cash left over-16億円Cash from the business, less what went into equipment.
Spent on equipment0百万円Plants, machines — things meant to last.
Employees12Headcount at the end of this period.
How to read this page
This is not the documentIt is Komori's reading of the filing submitted to EDINET. The original is linked above.
The score is not a verdictIt measures how specific the disclosure is. It says nothing about results or where the share price goes.
When it updatesContent lands once the filing has been read through. Right after submission, the summary can still be empty.